Biolase, Inc.

Biolase, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of September 30, 2024, Biolase, Inc. has 36.60M shares outstanding.

As of September 30, 2024, Biolase, Inc. maintains a current ratio of 0.63, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -357.57, indicating conservative leverage, while an interest coverage ratio of -4.51 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -48.61, reflecting losses generated across the asset base. The company generates approximately 293,159.24 in revenue per employee across its workforce of 157.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.55 indicates how many times Biolase, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2024, Biolase, Inc. recorded 36,000.00 in income tax expense. The company reported a pretax loss of -16.00M and -16.04M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Biolase, Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended September 30, 2024, Biolase, Inc. generated 46.03M in revenue and converted that into -16.04M in net income, yielding earnings per share of -0.71. EBITDA reached -10.90M, while operating income came in at -13.52M.

As of September 30, 2024, Biolase, Inc. holds 3.44M in cash and equivalents against 18.69M in total debt, resulting in a net debt position of 14.18M. Total book value stands at -5.23M, with working capital of -11.43M providing operational flexibility.

Biolase, Inc. produced -13.43M in operating cash flow over the twelve months ended September 30, 2024. After subtracting -252,000.00 in capital expenditures, free cash flow totaled -13.68M - equivalent to -0.61 per share.

Over the twelve months ended September 30, 2024, Biolase, Inc. posted a gross margin of 34.44, reflecting its pricing power and cost economics. The operating margin of -29.37 and net profit margin of -34.84 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. The dividend payout ratio of -0.44 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Biolase, Inc.'s most recent stock split took place on July 28, 2023 with a 100:1 split ratio.